TLC to Present at Cantor Virtual Global Healthcare Conference
September 11 2020 - 4:45AM
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty
pharmaceutical company developing novel nanomedicines to target
areas of unmet medical need, today announced that George Yeh,
President of TLC, will be discussing recent activities regarding
the company in a fireside chat with Kristen Kluska, Research
Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday,
September 15, 2020 at 10:00am ET.
The 30-minute fireside chat will be a Q&A
session in which Mr. Yeh will introduce TLC and talk about the
company’s leading programs: TLC599 for sustained relief of
osteoarthritis pain and TLC590 for sustained relief of postsurgical
pain, and introduce TLC19 for prevention and treatment of
COVID-19.
A recording of the fireside chat will be
available on the company’s website at www.tlcbio.com in the
Investors section, under News & Events.
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage
specialty pharmaceutical company dedicated to the research and
development of a diverse, wholly owned portfolio of novel
nanomedicines that maximize the potential of its proprietary
lipid-assembled drug delivery platform (LipAD™), including
BioSeizer® sustained release technology and NanoX™ active drug
loading technology, which are versatile in the choice of active
pharmaceutical ingredients and scalable in manufacturing.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not
guarantees of future performance and involve a number of risks,
assumptions, uncertainties and factors, including risks that the
outcome of any clinical trial is inherently uncertain and product
candidates may prove to be unsafe or ineffective, or may not
achieve commercial approval. Other risks are described in the
Risk Factors section of TLC’s annual report on Form 20-F for the
year ended December 31, 2019 filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
TLC’s expectations and assumptions as of the date of this press
release. Actual results may differ materially from these
forward-looking statements. Except as required by law, TLC
expressly disclaims any responsibility to update any
forward-looking statement contained herein, whether as a result of
new information, future events or otherwise.
Contact
Dawn Chi / Corporate Communications / dawn@tlcbio.com
Taiwan Liposome (NASDAQ:TLC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taiwan Liposome (NASDAQ:TLC)
Historical Stock Chart
From Apr 2023 to Apr 2024